Study of Modified Recombinant Factor VIII (OBI-1) in Subjects With Acquired Hemophilia A

Acquired Hemophilia A Clinical Trial

Official title:
Efficacy and Safety of B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies

Status Completed

Clinical Trial Summary

This study is to test whether the study drug (OBI-1) is safe and effective for the treatment of serious bleeding episodes in people with acquired hemophilia A.

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT01178294
Study type	Interventional
Source	Takeda
Contact
Status	Completed
Phase	Phase 2/Phase 3
Start date	November 10, 2010
Completion date	October 9, 2013

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT03700229` - Study to Evaluate Rituximab and Bortezomib in Patients With Newly Diagnosed Acquired Hemophilia A	Phase 2
Completed	`NCT04580407` - Study of TAK-672 in Participants With Acquired Hemophilia A	Phase 2/Phase 3
Completed	`NCT02610127` - Post-Marketing Non-Interventional Safety Evaluation of Obizur in the Treatment of Bleeding Episodes for Patients With Acquired Hemophilia A
Completed	`NCT03384277` - Trial of Acquired Haemophilia With Steroid Combined With Cyclophosphamide Versus Steroid Combined With Rituximab	Phase 4
Completed	`NCT03199794` - Prospective and Retrospective, Non-interventional Study to Evaluate the Safety and Effectiveness of Obizur in Real-life Practice
Recruiting	`NCT05345197` - Emicizumab in Patients With Acquired Hemophilia A	Phase 2
No longer available	`NCT01968655` - Expanded Access to B-Domain Deleted Recombinant Porcine Factor VIII (OBI-1) in the Treatment of Acquired Hemophilia A Due to Factor VIII Inhibitory Auto-antibodies